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Abstract
Purpose of Review Remarkable reductions in cardiovascular morbidity and mortality have been achieved in recent decades 
through the widespread use of ‘small-molecule’ hypolipidaemic drugs such as statins and ezetimibe. An alternative approach 
is to perturb the production of proteins through ribonucleic acid (RNA) silencing, leading to long-lasting knock-down of spe-
cific biological molecules. This review describes the scientific basis of RNA silencing, and critically evaluates the evidence 
relating to inclisiran, a small interfering RNA against proprotein convertase subtilisin kexin 9 (PCSK9).
Recent Findings Pooled analysis of three recent ORION trials has demonstrated that twice-yearly administration of inclisiran 
reduces LDL-C by 50% in a range of patient groups, with only mild adverse effects.
Summary Inclisiran provides safe, effective and long-lasting reductions in PCSK9 and LDL-C. The results of the phase-3 
ORION-4 outcomes study are eagerly awaited. Further promising RNA silencing technologies have the potential to improve 
the management of dyslipidaemia.
Keywords Inclisiran · LDL cholesterol · Dyslipidaemia · Atherosclerosis · siRNA
Introduction
Substantial reductions in cardiovascular morbidity and mor-
tality have been achieved in recent decades through the wide-
spread use of hypolipidaemic drugs, which act as enzyme 
inhibitors (statins) or modulate transporters (ezetimibe) or 
receptor proteins (fibrates) [1]. Whilst undoubtedly effec-
tive, these small-molecule agents have the disadvantages of 
off-target effects and require good compliance with daily 
dosing. An alternative approach is to perturb the produc-
tion of proteins through ribonucleic acid (RNA) silencing, 
leading to long-lasting knock-down of specific biological 
molecules, thus overcoming the need for daily dosing and 
potentially avoiding off-target biological effects. This review 
will describe the scientific basis of RNA silencing and criti-
cally evaluate the evidence relating to inclisiran (a small 
interfering RNA against proprotein convertase subtilisin 
kexin 9 (PCSK9)).
The clinical Need for New Pharmacological 
Approaches in Dyslipidaemia
Cardiovascular disease (CVD) prevention, and hypolipidae-
mic drugs, in particular, is a great successes story of modern 
medicine. Statins (which inhibit 3-hydroxy-3-methyl-glu-
taryl-coenzyme A (HMG-CoA) reductase, the rate-limiting 
step in the mevalonate pathway of hepatic cholesterol syn-
thesis) are safe, well-tolerated, and reduce the risk of major 
cardiovascular events by about one quarter, for each mmol/l 
reduction in low-density lipoprotein cholesterol (LDL-C) 
[2]. Additional LDL-C lowering with ezetimibe (which 
blocks the intestinal NPC1-like intracellular cholesterol 
transporter 1, thereby reducing the absorption of dietary 
cholesterol) leads to a further reduction in cardiovascular 
risk [3]. However, a substantial proportion of treated indi-
viduals do not reach their LDL-C treatment targets [4], and 
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these targets may be too liberal. An overwhelming body 
of evidence from intervention trials, observational studies 
and Mendelian randomisation shows that the risk of ath-
erosclerotic cardiovascular events, including myocardial 
infarction and ischaemic stroke, is strongly associated with 
lifetime exposure to LDL-C [5, 6••], thus highlighting the 
importance of the concept that ‘Lower better longer’ with 
respect to LDL-C, and other lipoproteins containing apoli-
poprotein B [7]. Where optimal levels of LDL-C cannot be 
met with current therapies, new approaches are needed, both 
in primary prevention [4] and especially in the secondary 
prevention of cardiovascular disease, where the likelihood 
of recurrent disease is very high [8]. Exciting advances 
have occurred in this field, including the recent develop-
ment of bempedoic acid, an orally active prodrug, which 
is activated specifically in the liver to inhibit ATP citrate 
lyase (an enzyme upstream of HMG-CoA reductase in the 
mevalonate pathway of cholesterol synthesis) [4]. Neverthe-
less, the ‘small-molecule’ approach to drug development is 
largely limited to biological targets with an enzymatic active 
site or known regulatory domain, whereas antibody-based 
approaches and RNA silencing are not [9].
Small molecules often have ‘off-target’ interactions 
resulting in adverse effects. In the case of statin therapy, 
muscle pain is associated with ‘statin intolerance’ whereby 
patients cannot take the drug at all or cannot escalate the 
dose sufficiently to reach treatment targets [10]. Whilst it 
has been clearly demonstrated that the vast majority of sta-
tin-associated muscle pain is attributable to the nocebo or 
drucebo effect (i.e. it results from the expectation of pain 
or misattribution rather than a pharmacological effect) [11, 
12], long-term compliance with statin therapy remains a 
problem [13].
Furthermore, it is increasingly apparent that even optimal 
management of LDL-C does not eliminate the risk of CV 
events. This residual risk results in part from inflammation 
[14, 15] and is amenable to pharmacological interventions 
[16, 17], thereby revealing new approaches to the manage-
ment of atherosclerosis, although not all the newly recog-
nised drug targets are easily amenable to specific small-
molecule therapeutic agents.
Finally, many small-molecule approaches have a ‘ceiling 
effect’, with biological redundancy or compensatory mecha-
nisms limiting the maximum effect of the drug. For example, 
statin therapy results in upregulation of PCSK9 (the func-
tions of which are described in greater detail below), limit-
ing the extent of achievable LDL-C lowering [18••]. This 
can be a particular problem in specific groups of patients, 
such as those with familial hypercholesterolaemia (FH), who 
require a profound lowering of LDL-C to avoid the develop-
ment of atherosclerotic disease [19–21].
Alternative approaches to targeting molecules impor-
tant in the pathophysiology of atherosclerosis include 
monoclonal antibodies mAbs and RNA silencing techniques, 
which have the potential to overcome many of the limitations 
of ‘small-molecule’ approaches. Both approaches require 
injectable therapies and have the potential to result in longer 
lasting and more specific biological activities compared with 
orally active small molecules but differ in various respects. 
mAbs act predominantly by binding to extracellular proteins, 
whereas RNA-based therapies must enter cells to prevent 
the translation of mRNA. All examples of mAbs and RNA 
therapeutics used in humans to date require subcutaneous 
injections for administration and have the potential for injec-
tion site reactions. The effectiveness of monoclonal antibody 
therapies can be reduced by the development of autoantibod-
ies, although such an effect has not yet been observed with 
RNA-based drugs. mAbs are comparatively complex and 
expensive to produce in comparison to RNA-based drugs 
[9].
Inhibition of PCSK9 in the Prevention 
of Cardiovascular Disease
PCSK9 has emerged in recent years as an important target 
in the management of atherosclerosis and has been targeted 
by monoclonal antibody drugs (evolocumab and alirocumab) 
[22••] and inclisiran [23], leading to substantial reductions 
in LDL-C. LDL is cleared from plasma by binding with 
hepatic LDL receptors (LDL-R), causing the lipoprotein par-
ticles to be taken up into hepatocytes. PCSK9 is a key regu-
lator of LDL-R. The binding of LDL-R to PCSK9 results 
in internalisation and degradation of the receptor, reducing 
the capacity of the hepatocytes to take up LDL particles 
from the circulation. Monoclonal antibody PCSK9 inhibitors 
(alirocumab and evolocumab) bind to PCSK9 and prevent its 
interaction with LDL-R, thereby increasing the density of 
LDL-R on the cell surface. This approach has been demon-
strated to reduce cardiovascular events in large randomised 
controlled trials [22••]. Inclisiran produces a long-lasting 
reduction in PCSK9 by silencing mRNA for PCSK9, thereby 
increasing LDL-R on the cell surface. Statins reduce cho-
lesterol production by inhibition of HMG-CoA reductase, 
the rate-limiting step in the mevalonate pathway. The sub-
sequent depletion of cholesterol in hepatocytes leads to an 
upregulation of LDL-R on the cell surface (Fig. 1).
Inclisiran: Mechanism of Action
Inclisiran (previously designated as ALN-PCSsc, ALN-
60212) is the first example of an approved synthetic small 
interfering RNA (siRNA) drug for treating FH [24]. The 
siRNA molecule inhibits the expression of PCSK9 by 
binding to the host mRNA strand encoding for the protein, 
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causing it to cleave and degrade. This reduces the avail-
ability of the PCSK9 enzyme, which would otherwise 
block LDL receptors from initiating ingestion of LDL 
particles from the extracellular fluid. Inclisiran can there-
fore reduce blood concentration of LDL, with measurable 
clinical effects.
RNA interference (RNAi), as the biological basis for a 
subcategory of gene therapy, is a highly precise approach 
to suppressing the expression of specific genes [25]. This 
pathway is a cellular mechanism for defending against the 
effects of foreign genetic material being introduced into 
an organism, for example, through infection with a virus. 
RNAi can be exploited pharmaceutically to target and sup-
press genes that have been associated with diseases, with 
the added benefit of greater personalisation of therapeutics 
through sequence specificity [26].
RNAi can be achieved by two types of small double-
stranded RNA molecule, namely small interfering RNA 
(siRNA) and microRNA (miRNA), both of which suppress 
gene expression according to their specific sequence albeit 
in slightly different ways: miRNA mediates the repression 
of mRNA translation, whereas siRNA mediates mRNA deg-
radation. These differences provide a range of therapeutic 
possibilities, with the potential for one miRNA drug to target 
a number of different selected genes together, whereas an 
siRNA drug is able to target a single specific gene of interest. 
The focus of this review is on siRNA technology.
Once in the cytoplasm of a hepatocyte, the double-
stranded siRNA drug inclisiran is uncoiled into two single, 
short RNA strands, one of which acts as the guide strand 
whilst the other becomes the passenger, which has no fur-
ther role to play and is degraded [24, 27]. The inclisiran 
Fig. 1  Mechanisms of action of lipid-lowering drugs in hepatocytes. 
(1) LDL is cleared from plasma through binding with LDL receptor 
(LDL-R) and internalisation; LDL-R binds to PCSK9 and is internal-
ised and degraded. (2) Monoclonal antibody PCSK9 inhibitors (ali-
rocumab and evolocumab) bind to PCSK9 and prevent its interaction 
with LDL-R, thereby increasing LDL-R on the cell surface. (3) Incli-
siran produces long-lasting reduction in PCSK9 by silencing mRNA 
for PCSK9, thereby increasing LDL-R on the cell surface. (4) Statins 
reduce cholesterol production by inhibition of HMG-CoA reduc-
tase, the rate-limiting step in the mevalonate pathway; this leads to 
an upregulation of LDL-R on the cell surface. Abbreviations: CoA, 
coenzyme A; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-coenzyme 
A; LDL, low-density lipoprotein; MoAbs, monoclonal antibodies; 
mRNA, messenger ribonucleic acid; PCSK9 proprotein convertase 
subtilisin kexin 9; RISC, RNA-induced silencing complex (figure was 
created with biorender.com)
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guide strand becomes bound to the RNA-induced silencing 
complex (RISC) and then pairs with the complementary 
mRNA strand for PCSK9. The RISC argonaute enzymes 
then cleave the PCSK9 mRNA sequence where it is bound 
to the corresponding inclisiran guide strand, effectively 
silencing the PCSK9 gene. With a reduced synthesis of 
the PCSK9 protein, LDL-C concentration in the blood 
plasma is reduced. Following mRNA cleavage, the incli-
siran/RISC complex remains intact and retains its activity 
for further interference with gene expression of PCSK9, 
meaning that a single siRNA inclisiran molecule has some 
considerable long-term efficacy. Although only a small 
percentage of inclisiran administered becomes active in 
the hepatocytes, that which forms part of an inclisiran/
RISC complex has a very long half-life allowing dosing 
in patients to be months apart [24].
As an alternative to double-stranded siRNA, RNA silenc-
ing can be achieved with single-stranded antisense oligonu-
cleotides. These molecules ate typically 15–30 nucleotides 
in length and bind to mRNA, and prevent its translation, or 
cause its degradation [28].
Whilst siRNA therapeutics has been in development for 
around 20 years [29] for a number of different diseases, until 
recently, siRNA drugs have suffered drawbacks in terms of 
chemical stability and drug delivery [30, 31], which has 
prevented some promising candidates from becoming clini-
cally useful. Simple, unmodified siRNA tends to be unsta-
ble, being susceptible to enzymatic degradation by RNases, 
and following injection, siRNA molecules are destroyed by 
endonucleases and exonucleases before they can reach the 
target cells [32]. Off-target effects are also possible since the 
RISC will allow a small number of sequence mismatches 
with the siRNA guide strand, meaning that unrelated genes 
with very similar sequences may also be silenced. Therefore, 
chemical modification and drug delivery methods have been 
developed in attempts to improve the overall acceptability of 
siRNA technology in the clinic.
Drug delivery technology has generally been improved, 
partly to protect the otherwise naked siRNA drug and partly 
to overcome obstacles in the way of reaching the intended 
target. In an early siRNA drug known as ALN-PCS, which 
targeted the PCSK9 gene by encapsulating the drug within 
lipid nanoparticles, it was possible to increase the drug 
half-life and increase endocytosis into target cells [33]. 
RNA drugs are large molecules, when compared with typi-
cal small-molecule compounds, and also carry a negative 
electrical charge—both properties decrease the likelihood 
of entering the cell across the lipid bilayer. Therefore, lipid 
nanoparticle encapsulation helps to overcome these draw-
backs and aids intracellular delivery [34]. And because the 
liver is the primary filter for nanoparticles [35], it is possible 
to design novel siRNA drugs for dyslipidaemia that can tar-
get hepatocytes through this means [36].
Chemical conjugation is another method that has been 
employed to improve the stability and delivery of siRNAs. 
A covalently bound conjugate allows the siRNA drug to 
be targeted to specific tissues or cells by binding to a cell 
surface receptor, followed by entry through receptor-medi-
ated endocytosis. Following on from ALN-PCS, an siRNA 
for PCSK9, known as ALN-PCSsc, was conjugated with 
N-acetylgalactosamine (GalNAc), which allowed the drug 
to target hepatocytes via the asialoglycoprotein receptor [37, 
38]. The siRNA in inclisiran is also conjugated with Gal-
NAc, building on this earlier approach [24].
Inclisiran: Clinical Evidence and Guidelines
Inclisiran has been evaluated in a range of clinical trials 
(Table 1), including secondary prevention populations, high-
risk primary prevention and individuals with homozygous 
FH (HoFH) or heterozygous FH (HeFH) [23]. Character-
istics of ongoing and completed trials are summarised in 
Table 1, with their results (where available). Pooled analyses 
of currently available data are reassuring with respect to the 
safety and efficacy of inclisiran.
A patient-level pooled analysis including 3,660 patients 
from three ORION trials has recently been published. The 
analysis included data from patients with familial hyper-
cholesterolaemia (ORION-9), ASCVD (ORION-10) and 
ASCVD risk equivalents (ORION-11); 92% of subjects were 
taking statin therapy and 14% were using ezetimibe. Patients 
were injected with inclisiran or placebo at baseline, after 
3 months and then every 6 months. At 510 days, LDL-C 
was found to be reduced by 50.7% [95% confidence inter-
vals − 48.9, 52.1%] in the inclisiran group, after correction 
for placebo. Adverse effects included bronchitis and mild 
injection site reactions.
A pre-specified safety analysis of the ORION-1 trial (501 
patients) focused on haematological variables during a year 
of follow-up. No evidence was found that inclisiran affected 
counts of leucocytes, monocytes, platelets or neutrophils 
[45, 46]. Inflammatory markers (including IL6 and TNF-
alpha) were not affected by inclisiran treatment. Provided 
these observations are replicated in larger trials, the drug is 
likely to have a very good safety profile.
Outcomes data available to date are extremely promising. 
A meta-analysis including data from ORION-10, ORION-
11 and studies investigating MoAb-based PCSK9 inhibitors 
found that the relationship between LDL-C lowering and 
reduction in MACE followed the same trend for inclisiran 
and the MoAb agents [47]. A separate study pooling the 
results of ORION-9, ORION-10 and ORION-11 (a total of 
3,660 patients) demonstrated a 24% reduction in MACE with 
inclisiran treatment, compared to placebo [48]. A particular 
advantage of inclisiran over other lipid-lowering therapies is 
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Table 1  Summary of clinical trials evaluating inclisiran
Abbreviations: ASCVD atherosclerotic cardiovascular disease; CV cardiovascular; HeFH heterozygous familial hypercholesterolaemia, HoFH 
homozygous familial hypercholesterolaemia; LLT lipid-lowering therapy; LDL-C low-density lipoprotein cholesterol; MACE major adverse car-
diovascular events
Phase Dates Participants (n) Population Primary outcome Results
ORION-1 NCT02597127 II 2016–2017 501 High CV risk and 
elevated LDL-C
% change in LDL-C LDL-C ↓ between 
29.5% and 46.4% 
[39]
ORION-2 NCT02963311 II 2016–2018 5 HoFH % change in LDL-C LDL-C ↓
PCSK9 ↓ [40]
ORION-3 NCT03060577 II 2017–2022 High CV risk and 
elevated LDL-C




NCT03705234 III 2018–2026 15,000 ASCVD MACE Not available
ORION-5 NCT03851705 III 2020–2021 56 HoFH % change in LDL-C Not available
ORION-7 NCT03159416 I 2017–2018 31 Comparing patients 
with renal impair-




Inclisiran safe in renal 
impairment [41]
ORION-8 NCT03814187 III 2019–2023 2991 High CV risk and 
elevated LDL-C




ORION-9 NCT03397121 III 2017–2019 482 HeFH % change in LDL-C LDL-C ↓ 53.8%[42]
ORION-10 NCT03399370 III 2017–2019 1561 ASCVD and elevated 
LDL-C
Absolute change in 
LDL-C
LDL-C ↓ 47.2%[43]
ORION-11 NCT03400800 III 2017–2019 1617 ASCVD or risk 
equivalents and 
elevated LDL-C
Absolute change in 
LDL-C
LDL-C ↓ 47.9%[43]
ORION-13 NCT04659863 III 2021–2023 15 Adolescent HoFH 
patients
% change in LDL-C Not available





ORION-16 NCT04652726 III 2021–2023 150 Adolescent HeFH 
patients
% change in LDL-C Not available
V-INCEPTION NCT04873934 III 2021–2023 384 Recent ACS and 
LDL-C > 70 mg/dl
% change in LDL-C Not available
SPIRIT NCT04807400 III 2021–2022 900 Patients on estab-
lished LLT or have 
previously not toler-
ated LLT
% change in LDL-C Not available
NA NCT04666298 II 2021–2022 308 Japanese patients with 
high cardiovascular 
risk and elevated 
LDL-C
% change in LDL-C Not available
NA NCT04765657 III 2021–2022 320 Asian patients with 
ASCVD or risk 
equivalents and 
elevated LDL-C
% change in LDL-C Not available
NA NCT02314442 I 2015–2016 70 Healthy volunteers Adverse events No serious adverse 
events [24]
NA NCT01437059 I 2011–2012 32 Healthy volunteers Adverse events No serious adverse 
events
LDL-C ↓ 40%
PCSK9 ↓ 70% [44]
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the fact that it can be safely used in patients with mild (CrCl 
60–89 mL/min), moderate (CrCl 30–59 mL/min) or severe 
(CrCl 30–59 mL/min) renal function impairment, without 
the need for dose adjustment, thereby addressing an unmet 
need, particularly in the secondary prevention of cardiovas-
cular disease [41].
On the basis of these data, inclisiran is likely to play an 
increasing role in guideline-directed management of dyslipi-
daemias. Polish guidelines recommend that inclisiran may 
be considered in patients with ASCFD or FH who do not 
achieve lipid targets on statin and ezetimibe, in statin intoler-
ance and in very high-risk primary prevention patients who 
do not adhere to, or consent to, other lipid-lowering therapies 
[49]. In the UK, the National Institute for Health and Care 
Excellence (NICE) is currently evaluating inclisiran for the 
treatment of primary hypercholesterolaemia or mixed dys-
lipidaemia [50]. Current recommendations and marketing 
approvals are based on the data showing robust long-term 
reduction of circulating LDL-C by inclisiran. More wide-
spread use of inclisiran may be expected if it is demonstrated 
to reduce hard clinical outcomes to the extent that would be 
expected, given the success of MoAb-based PCSK9 inhibi-
tors. The ongoing HPS-4/TIMI 65/ORION-4 double-blind 
randomised controlled clinical trial (NCT03705234) will 
provide important information in this respect. The study is 
currently recruiting 15,000 individuals with ASCVD at 180 
clinical sites in the UK and the USA. Participants will be 
randomised in a 1:1 ratio to receive a placebo injection, or 
subcutaneous injection of inclisiran sodium 300 mg will be 
administered as at randomisation, 3 months and then every 
6 months, and will be followed up for 5 years with a pri-
mary composite endpoint of the first occurrence of coronary 
heart disease death; myocardial infarction; fatal or non-fatal 
ischemic stroke; or urgent coronary revascularisation proce-
dures (Table 1) [51].
Whilst inclisiran is the first drug in its class for dyslipi-
daemia, it is unlikely to be the only one since RNA inhi-
bition offers, at least theoretically, the opportunity to tar-
get any gene of interest. The siRNA templates are already 
established, and therefore, it is a simple step to modify the 
sequence of nucleic acids to a specific target mRNA. Other 
proteins associated with plasma lipid homeostasis, particu-
larly if they are functional in the liver, are therefore likely 
to be included in research and development programmes 
using this technology. An orally available antisense oligo-
nucleotide for PCSK9 has recently demonstrated promise 
in preclinical studies [52], and RNA silencing is currently 
under investigation to target a range of proteins implicated 
in the pathophysiology of atherosclerosis (Table 2).
Conclusions
Pooled analysis of three recent ORION trials has demon-
strated that twice-yearly administration of inclisiran reduces 
LDL-C by 50% in a range of patient groups, with only 
mild adverse effects. Inclisiran, therefore, is a safe, effec-
tive approach to the reduction of LDL-C. The results of the 
phase-3 ORION-4 outcomes study are eagerly awaited and 
will demonstrate the effectiveness of inclisiran against hard 
clinical outcomes. Further promising RNA silencing tech-
nologies directed at a variety of biological targets have the 
potential to improve the management of dyslipidaemias.
Table 2  RNA silencing therapeutics in development or use for dyslipidaemias





Demonstrated Lp(a) reduction 
in Phase II [53]
AMG890 Olpasiran siRNA Phase I (NCT03626662)
Phase II (NCT04270760)
Apolipoprotein CIII Lowers serum triglycerides Volanesorsen Antisense oligonucleotide In clinical use
AKCEA-APOCIII-LRX Antisense oligonucleotide Phase III (NCT04568434)
Apolipoprotein B Apolipoprotein B is an essen-
tial component of athero-
genic lipoproteins, including 
LDL
Mipomersen Antisense oligonucleotide In clinical use
ANGPTL3 ANGPTL3 inhibition reduces 
triglyceride and LDL and 
lowers cardiovascular risk
AKCEA-ANGPTL3-LRX GalNAc-conjugated antisense 
oligonucleotide
Improved lipid profile in phase 
I trial [54]
Awaiting results of phase II 
trial (NCT03371355)
PCSK9 PCSK9 inhibition increases 
LDL-R density on hepato-
cytes and improves LDL 
particle clearance from the 
blood
Inclisiran siRNA Phase III [23]
AZD8233 Antisense oligonucleotide 
(orally available)
Preclinical studies [52]
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